<i>TP53</i> Signature Can Predict Pathological Response From Neoadjuvant Chemotherapy and Is a Prognostic Factor in Patients With Residual Disease.

Breast Cancer (Auckl) · 2023 · PMC10170595 · PMID 37181950

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the ER-positive subtype, there was no significant difference in RFS between the pCR group and RD/ TP53 mutant signature group, but the latter showed a trend toward poor prognosis ( Supplemental Figure 1b ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.